Insulin oral - Generex Biotechnology
Alternative Names: Insulin buccal - Generex; Oral Recosulin; Oral-lyn; Oral-Lyn-2; OralgenLatest Information Update: 21 Jan 2022
At a glance
- Originator Generex Biotechnology Corporation
- Developer Generex Biotechnology Corporation; Leosons
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Discontinued Glucose intolerance
Most Recent Events
- 04 Jul 2019 Oral insulin is till in under regulatory review for Type 2 diabetes in Jordan, Kuwait, Qatar
- 04 Jul 2019 Oral insulin is till in under regulatory review for Type 1 diabetes in Jordan, Kuwait, Qatar
- 23 Mar 2017 Discontinued - Phase-II for Glucose intolerance in Italy (Buccal) (Generex Biotechnology Corporation pipeline, March 2017)